GlucoTrack

GCTK

시가총액 US$73.8만

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack, Inc. Announces Pricing of $3 Million Public Offering.

Shares of GlucoTrack Inc (NASDAQ:GCTK) rose sharply in pre-market trading following the announcement that its subsidiary, Lokahi Therapeutics, signed its first external, fee-for-service partnership.

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi CEO Erik Emerson outlines LT-100 progress, ai² platform growth, and a strategy to discover, advance, and monetize assets.

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)-- #Glucotrack--Glucotrack announces $11.5M convertible note financing, including new capital and note rollover, to support strategic growth.

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack (Nasdaq: GCTK) announced a 1-for-15 reverse stock split effective August 31, 2026, to support Nasdaq listing compliance.

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--"We are approaching the months ahead with confidence, urgency, and a clear sense of purpose," said Erik Emerson, CEO of Glucotrack.

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it acted as exclusive financial advisor in connection with a $5.5 million financing for Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK).

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack, Inc. (NASDAQ: GCTK) ("Glucotrack" or the "Company") today announced definitive agreements for approximately $5.5 million in financing from participating institutional investors, including a $2.0 million equity financing priced at $0.75 per unit and a $3.5 million follow-on investment in the form of convertible debt. The equity financing consists of units priced at $0.75 per unit, with each unit comprised of one share of common st.

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack (NASDAQ: GCTK) today announced the continued expansion of the ai² Futures Lab™ operated through its wholly owned subsidiary, Lōkahi Therapeutics™ Inc. During its first year, the ai² Futures Lab™ identified more than 45 therapeutic opportunities on a budget of approximately $33,000 and advanced five into active company discussions. These assets represent more than $500 million in prior biopharmaceutical investment and include oppor.

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced progress in its LT-100 development strategy focused on evaluating whether a historical administration approach requiring up to 15 intradermal (ID) injections per treatment visit can be simplified to a single subcutaneous (SC) injection per visit. During a Type C meeting with the U.S. Food and Drug Administration in May 2026, the Company d.